Diagnostics World | Fresenius expands its access to innovation networks through its own corporate venture capital fund over the next five years; Transcripta Bio's closed-loop discovery engine is designed to use transcriptomic signature matching to identify drugs whose molecular signatures are the inverse of patient-derived disease signatures; and more.
